Ezetimibe/simvastatin combination not found to increase cancer risk, mortality
the ONA take:
According to a new study published in the American Journal of Cardiology, researchers have found that treatment with ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer or an increased risk of cancer-related mortality.
Researchers identified 1,359 eligible patients for follow-up from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study so that they could investigate new incidences of cancer and total mortality over 21 months following the end of the SEAS trial. Of the 1,359 patients, 1,194 had no history of cancer cancer.
In that portion of patients, 12 patients who received ezetimibe/simvastatin had developed cancer and 22 patients that received placebo developed cancer in the 21-month follow-up (HR 0.55, 95% CI 0.27 - 1.11). During the same period, 43 patients who received ezetimibe/simvastatin and 33 who received placebo died (HR 1.29, 95% CI 0.82 - 2.03).
Results suggest that treatment with the lipid-lowering combination was not linked with an increased risk for developing cancer or dying from cancer during the 21-month follow-up to the SEAS trial. Numerous authors reported financial disclosures with Merck & Co., the manufacturer of Vytorin.
Ezetimibe/simvastatin (Vytorin) is not linked with an elevated risk for developing cancer.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|